Skip navigation
  • 中文
  • English

DSpace CRIS

  • DSpace logo
  • Home
  • Organizations
  • Researchers
  • Research Outputs
  • Explore by
    • Organizations
    • Researchers
    • Research Outputs
  • Academic & Publications
  • Sign in
  • 中文
  • English
  1. NTU Scholars
  2. 醫學院
  3. 牙醫專業學院
  4. 臨床牙醫學研究所
Please use this identifier to cite or link to this item: https://scholars.lib.ntu.edu.tw/handle/123456789/570742
Title: Ketoconazole potentiates the antitumor effects of nocodazole: In vivo therapy for human tumor xenografts in nude mice
Authors: Wang Y.-J.
JIIANG-HUEI JENG 
Chen R.-J.
Tseng H.
Chen L.-C.
Liang Y.-C.
Lin C.-H.
Chen C.-H.
Chu J.-S.
Ho W.-L.
Ho Y.-S.
Keywords: Apoptosis; Ketoconazole; Nocodazole; Nude mice; p27/KIP1
Issue Date: 2002
Journal Volume: 34
Journal Issue: 4
Start page/Pages: 199-210
Source: Molecular Carcinogenesis
Abstract: 
Our previous studies demonstrated that the oral antifungal agent Ketoconazole (KT) induces apoptosis and G0/G1 phase cell cycle arrest in human cancer cell lines. In this study, we first demonstrated that KT (1 μM) potentiated the apoptotic effects of nocodazole (ND, 1 nM) in COLO 205 cancer cells. We further demonstrated the therapeutic efficacy of a combined treatment of KT (50 mg/kg/three times per week) and ND (5 mg/kg/three times per week) in vivo by treating athymic mice bearing COLO 205 tumor xenografts. The antitumor effects of ND were significantly potentiated by KT in mice after 6 wk of treatment. No gross signs of toxicity were observed in mice receiving these treatment regimens. The apoptotic cells were detected in a microscopic view of the terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling staining and by observation of DNA fragmentation in KT + ND-treated tumor tissues. The levels of cell cycle regulatory proteins were determined by Western blot analysis. Treatment with KT inhibits tumor growth through elevation of p53, p21/CIP1, and p27/KIP1 as well as inhibition of cyclin D3 and cyclin-dependent kinase 4 protein expression. Immunohistochemical staining analysis showed that p53, p21/CIP1, and p27/KIP1 immunoreactivity were induced in the tumor tissues. To clarify the roles of the p21/CIP1 and p27/KIP1 protein expression involved in G0/G1 arrest and/or apoptosis induced by a combined treatment with KT and ND, antisense oligodeoxynucleotides (ODNs) specific to p21/CIP1 and p27/KIP1 were used. Our results demonstrated that apoptotic phenomena, including BAX induction and cytochrome C released from mitochondria induced by KT + ND, were significantly attenuated by pretreatment the cells with the p27/KIP1-specific antisense ODNs. These results indicate that p27/KIP1 protein does indeed play a critical role in the KT + ND-induced apoptosis. Our study revealed the molecular mechanism of KT + ND in regression of the tumor growth. The apoptotic effects of KT in a great variety of cancer cells make it a very attractive agent for cancer chemotherapy. ? 2002 Wiley-Liss, Inc.
URI: https://www.scopus.com/inward/record.uri?eid=2-s2.0-0036322005&doi=10.1002%2fmc.10066&partnerID=40&md5=512f652ff68db115d9d45d4d16476a78
https://scholars.lib.ntu.edu.tw/handle/123456789/570742
ISSN: 0899-1987
DOI: 10.1002/mc.10066
SDG/Keyword: antisense oligodeoxynucleotide; cyclin D3; cyclin dependent kinase 4; cytochrome c; DNA fragment; DNA nucleotidylexotransferase; ketoconazole; nocodazole; protein Bax; protein p21; protein p27; animal experiment; animal model; antineoplastic activity; article; cancer cell culture; cancer inhibition; cell cycle G0 phase; cell cycle G1 phase; controlled study; drug activity; drug effect; drug mechanism; drug potentiation; enzyme release; gene induction; human; human cell; immunohistochemistry; mouse; nick end labeling; nonhuman; priority journal; protein expression; toxicity; tumor growth; tumor xenograft; Western blotting; Adenocarcinoma; Animals; Antifungal Agents; Antineoplastic Agents; Apoptosis; bcl-2-Associated X Protein; Carrier Proteins; Colonic Neoplasms; Cyclin-Dependent Kinase 4; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclin-Dependent Kinases; Cyclins; Cytochrome c Group; Drug Synergism; Humans; Intracellular Signaling Peptides and Proteins; Ketoconazole; Mice; Mice, Nude; Nocodazole; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays; Mus musculus
[SDGs]SDG3
Appears in Collections:臨床牙醫學研究所

Show full item record

SCOPUSTM   
Citations

20
checked on Mar 27, 2023

WEB OF SCIENCETM
Citations

21
checked on Mar 12, 2023

Page view(s)

9
checked on Mar 24, 2023

Google ScholarTM

Check

Altmetric

Altmetric

Related Items in TAIR


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

臺大位居世界頂尖大學之列,為永久珍藏及向國際展現本校豐碩的研究成果及學術能量,圖書館整合機構典藏(NTUR)與學術庫(AH)不同功能平台,成為臺大學術典藏NTU scholars。期能整合研究能量、促進交流合作、保存學術產出、推廣研究成果。

To permanently archive and promote researcher profiles and scholarly works, Library integrates the services of “NTU Repository” with “Academic Hub” to form NTU Scholars.

總館學科館員 (Main Library)
醫學圖書館學科館員 (Medical Library)
社會科學院辜振甫紀念圖書館學科館員 (Social Sciences Library)

開放取用是從使用者角度提升資訊取用性的社會運動,應用在學術研究上是透過將研究著作公開供使用者自由取閱,以促進學術傳播及因應期刊訂購費用逐年攀升。同時可加速研究發展、提升研究影響力,NTU Scholars即為本校的開放取用典藏(OA Archive)平台。(點選深入了解OA)

  • 請確認所上傳的全文是原創的內容,若該文件包含部分內容的版權非匯入者所有,或由第三方贊助與合作完成,請確認該版權所有者及第三方同意提供此授權。
    Please represent that the submission is your original work, and that you have the right to grant the rights to upload.
  • 若欲上傳已出版的全文電子檔,可使用Sherpa Romeo網站查詢,以確認出版單位之版權政策。
    Please use Sherpa Romeo to find a summary of permissions that are normally given as part of each publisher's copyright transfer agreement.
  • 網站簡介 (Quickstart Guide)
  • 使用手冊 (Instruction Manual)
  • 線上預約服務 (Booking Service)
  • 方案一:臺灣大學計算機中心帳號登入
    (With C&INC Email Account)
  • 方案二:ORCID帳號登入 (With ORCID)
  • 方案一:定期更新ORCID者,以ID匯入 (Search for identifier (ORCID))
  • 方案二:自行建檔 (Default mode Submission)
  • 方案三:學科館員協助匯入 (Email worklist to subject librarians)
Build with DSpace-CRIS - Extension maintained and optimized by Logo 4SCIENCE Feedback